Clinical Commander

All dossiers
cardio.cardiogenic-shock.covid-myocarditis.v1

Cardiogenic shock — COVID-19-associated myocarditis (infection or post-mRNA-vaccine)

cardiologyacuteadultacuteinpatienttransitionoutpatient
Start encounter →Print handoutPRODUCTION

Phase E variant of cardio.cardiogenic-shock.core.v1 — narrowed to COVID-19-associated myocarditis (acute infection + post-mRNA-vaccine forms) per AHA 2022 cardiovascular manifestations of COVID-19 (Gluckman PMID 35403432) + Patone Nat Med 2022 mRNA vaccine-associated myocarditis (PMID 35115708). Two phenotypes: (a) ACUTE COVID INFECTION myocarditis — peaked 2020-2021, rare with current Omicron variants per Buckley JACC 2024 + CDC surveillance, can be fulminant with cytokine storm, MIS-A overlap possible per Belay MMWR 2021; (b) POST-mRNA-VACCINE myocarditis — Pfizer / Moderna, peak in young males 16-29 yo post-dose 2 day 2-7 per Patone Nat Med 2022 + Mevorach NEJM 2021, usually mild + self-limited but rarely fulminant. Workup pivots: SARS-CoV-2 PCR + serology (anti-N differentiates prior infection from anti-S vaccine-induced); CMR Lake Louise 2018 (Ferreira JACC 2018 PMID 30025572 — vaccine myocarditis often inferolateral mid-myocardial LGE per Daniels Circulation 2021); high-sensitivity inflammatory markers (CRP, IL-6, ferritin) for cytokine storm screen and tocilizumab candidacy; MIS-A criteria check per CDC (Belay MMWR 2021); EMB reserved for fulminant + alternative etiology suspicion. Treatment ACUTE: standard CS support (NE first-line per SOAP-II PMID 20200382); inotropes CAUTIOUS in inflamed myocardium; MCS bridge (IABP / Impella / VA-ECMO) early — fulminant viral has high recovery rate (McCarthy NEJM 2000 PMID 10717012); ELSO 2020 ECMO myocarditis registry 60-70% survival. Phenotype-specific: ACUTE COVID with cytokine storm → tocilizumab 8 mg/kg IV per REMAP-CAP PMID 33631065 + RECOVERY tocilizumab PMID 33933206 (extrapolated from respiratory data); concurrent COVID respiratory failure → dexamethasone per RECOVERY PMID 32678530 (HELPS RESPIRATORY, NOT TRIAL-EVIDENCED for myocardial involvement — do not use steroids solely for myocarditis); IVIG 1-2 g/kg in fulminant per case series (Robinson Lancet 2020) + MIS-A; nirmatrelvir-ritonavir if within 5 d symptom onset and eGFR ≥30 (EPIC-HR PMID 35172054 — check extensive CYP3A4 interactions); AVOID NSAIDs in fulminant per ESC 2013. VACCINE-ASSOCIATED usually mild — NSAID (aspirin 650-1000 TID) + colchicine 0.6 BID × 3 mo + supportive (ACC 2022 / AHA 2021); 24-48 h hospital observation; troponin trend; echo at 24-48 h; mRNA vaccine continuation per CDC ACIP shared decision (alternative vaccine considered); no competitive sports × 3-6 mo per AHA 2015 / ESC 2020 / Drezner JACC 2022. Fulminant vaccine pattern (rare, post-dose 2 young male) escalates to fulminant myocarditis pathway with future mRNA dose contraindicated. Inherits parent CS framework; specialises for COVID inflammatory etiology — COVID-specific diagnostics (PCR, serology, MIS-A criteria, CMR pattern), COVID-specific therapeutics (tocilizumab, antiviral, dexamethasone for respiratory only, IVIG, NSAID + colchicine for vaccine mild); falls back to cardio.cardiogenic-shock.viral-myocarditis.v1 sibling for general fulminant viral framework. Status INTEGRATED until terminology + RxNav-validated drug codes are reconciled. Authored 2026-05-15 by shard-06-cardio-acute as Phase E wave 14 etiology variant.

Entry points (5)

  • symptom
    Acute COVID-19 infection (PCR+ within past 4 weeks) with new acute heart failure + cardiogenic shock physiology — acute COVID myocarditis with CS
    acute_covid_infection_with_acute_hf_and_shock
  • history
    Recent mRNA COVID vaccine (Pfizer / Moderna) within 2-7 days + acute chest pain ± dyspnea ± troponin elevation, especially young male <30 — vaccine-associated myocarditis (usually mild but rarely fulminant)
    recent_mrna_vaccine_with_acute_chest_pain
  • imaging
    Cardiac MRI: T2 edema + LGE (sub-epicardial / mid-myocardial, often inferolateral in vaccine cases) + abnormal native T1/T2 (≥2 of 3 = Lake Louise 2018) + recent COVID exposure or vaccination
    cmr_lake_louise_with_recent_covid_exposure
  • lab_abnormality
    Markedly elevated troponin + elevated CRP + IL-6 + ferritin (cytokine storm pattern) + acute biventricular dysfunction post-COVID infection
    troponin_elevated_with_cytokine_storm_pattern_post_covid
  • symptom
    MIS-A (multisystem inflammatory syndrome in adults) with fever + ≥2 organ involvement + lab inflammation + recent SARS-CoV-2 evidence + cardiac dysfunction (CDC criteria, Belay MMWR 2021)
    mis_a_with_cardiac_involvement

Required inputs (22)

  • agerequired
    demographic • used at CONTEXT
    Age stratifies vaccine myocarditis risk (peak 16-29 yo male) vs acute COVID severity (older adults with comorbidities at higher risk)
  • sexrequired
    demographic • used at CONTEXT
    Vaccine-associated myocarditis predominantly young males; informs phenotype probability
  • sbprequired
    vital • used at RED_FLAGS
    SCAI 2022 staging baseline; gates vasopressor escalation
  • hrrequired
    vital • used at CONTEXT
    Tachyarrhythmia possible; transient AV block reported in vaccine cases
  • spo2required
    vital • used at INITIAL_WORKUP
    Concurrent COVID respiratory failure may co-exist in acute infection phenotype; informs ventilation + dexamethasone candidacy
  • troponinrequired
    lab • used at INITIAL_WORKUP
    Markedly elevated typical; trend correlates with severity; persistent elevation suggests ongoing myocyte injury
  • bnp_ntprobnprequired
    lab • used at INITIAL_WORKUP
    Acute HF marker; trend tracks recovery
  • lactaterequired
    lab • used at RISK_STRATIFICATION
    SCAI 2022 staging + CardShock prognostication (Harjola EHJ 2015 PMID 26333869)
  • creatininerequired
    lab • used at CONTEXT
    End-organ damage marker + dose adjustment + gadolinium safety screen for CMR
  • crprequired
    lab • used at INITIAL_WORKUP
    Cytokine storm marker; informs tocilizumab candidacy in acute COVID phenotype
  • il_6
    lab • used at INITIAL_WORKUP
    Elevated >40 pg/mL supports cytokine storm and tocilizumab candidacy per REMAP-CAP / RECOVERY
  • ferritinrequired
    lab • used at INITIAL_WORKUP
    Cytokine storm / hyperinflammation marker; MIS-A diagnostic criterion
  • d_dimerrequired
    lab • used at INITIAL_WORKUP
    COVID-associated VTE risk screening; baseline for anticoagulation decision
  • cbc_with_diffrequired
    lab • used at INITIAL_WORKUP
    Lymphopenia in COVID; eosinophilia argues against COVID etiology and toward eosinophilic myocarditis
  • sars_cov2_pcrrequired
    lab • used at INITIAL_WORKUP
    Establishes active acute infection vs prior; informs antiviral candidacy (nirmatrelvir-ritonavir if within 5 d)
  • sars_cov2_serology
    lab • used at BRANCHING_WORKUP
    Anti-N supports prior infection (not vaccine-induced); anti-S confounded by vaccination; helps differentiate acute infection vs post-vaccine phenotype
  • echorequired
    imaging • used at INITIAL_WORKUP
    Biventricular dysfunction; effusion screen; no regional wall motion crossing single coronary territory
  • ecgrequired
    imaging • used at INITIAL_WORKUP
    Diffuse ST/T-wave changes; PR depression if pericarditis overlap; AV block uncommon (more typical of giant cell)
  • cor_angiorequired
    imaging • used at BRANCHING_WORKUP
    Mandatory rule-out of obstructive CAD when shock with troponin elevation; especially important in older adults; clean coronaries support myocarditis differential
  • cmrrequired
    imaging • used at BRANCHING_WORKUP
    Lake Louise Criteria 2018 (Ferreira PMID 30025572); vaccine myocarditis often shows inferolateral mid-myocardial LGE per Daniels Circulation 2021
  • recent_mrna_vaccine_historyrequired
    history • used at CONTEXT
    mRNA vaccine within 2-7 days, dose number, manufacturer (Pfizer / Moderna) → vaccine-associated myocarditis differential
  • recent_covid_infection_historyrequired
    history • used at CONTEXT
    Active or recent (within 4 wks) SARS-CoV-2 infection by PCR, antigen, or serology → acute infection phenotype

12-phase flow (11)

  1. 1FRAME
    Confirm COVID-associated myocarditis etiology — recent infection (PCR+ within 4 wks) OR recent mRNA vaccination (within 2-7 d, especially young male <30); biventricular dysfunction, no obstructive CAD, troponin elevation; identify phenotype (acute infection vs post-vaccine vs MIS-A overlap) which drives diagnostic + treatment pathway
    inputs: echo, cor_angio
    advance: COVID-myocarditis confirmed and phenotype hypothesis stated
  2. 2ENTRY
    CS team activation; emergency cath to exclude obstructive CAD (mandatory MI mimic rule-out); echo for biventricular function + effusion; mobilize MCS team early — fulminant viral has high recovery rate
    inputs: sbp, lactate
    advance: CS team activated + obstructive CAD excluded + MCS team aware
  3. 3CONTEXT
    Recent COVID infection (within 4 wks), recent mRNA vaccine (within 2-7 d), dose number, manufacturer; allergic reactions; oncology / immunosuppression status; respiratory symptoms (concurrent COVID pneumonia); MIS-A criteria check
    inputs: age, sex, hr, creatinine, recent_mrna_vaccine_history, recent_covid_infection_history
    advance: Context complete and phenotype stated
  4. 4RED_FLAGS
    Cytokine storm with multi-organ failure (acute COVID); fulminant vaccine-associated pattern (rare but described — usually post-dose 2 in young males); transient high-grade AV block; large pericardial effusion → tamponade; concurrent COVID respiratory failure requiring ventilation; MIS-A overlap
    inputs: sbp, spo2
    actions: cardiogenic_shock, cardiac_tamponade
    advance: Red flags screened; MCS pathway engaged if needed
  5. 5INITIAL_WORKUP
    ECG, echo, troponin, BNP, BMP, lactate, CBC w/ diff, CRP, ferritin, IL-6 (if available), d-dimer, SARS-CoV-2 PCR + serology; serial telemetry; SCAI 2022 staging
    inputs: ecg, echo, troponin, bnp_ntprobnp, lactate, cbc_with_diff, crp, ferritin, d_dimer, sars_cov2_pcr, spo2
    actions: cardiogenic_shock, panel.cardiac, panel.renal, panel.abg, panel.cbc
    advance: Workup complete and SCAI stage assigned
  6. 6BRANCHING_WORKUP
    Cardiac MRI (Lake Louise 2018) when stable; emergency angiography to exclude obstructive CAD; viral PCR panel (parvovirus B19, HHV-6, enterovirus, adenovirus, EBV) to rule out other viruses; SARS-CoV-2 anti-N serology to differentiate prior infection vs vaccine-induced anti-S; endomyocardial biopsy if life-threatening + alternative etiology suspected (giant cell, eosinophilic — diagnosis-changing)
    inputs: cor_angio, cmr
    advance: Phenotype confirmed by CMR ± EMB ± serology
  7. 7RISK_STRATIFICATION
    SCAI 2022 staging; CardShock prognostication; phenotype drives prognosis (vaccine-associated usually mild + recovers in days-weeks; acute COVID severe — mortality higher with cytokine storm + MIS-A overlap; fulminant viral has paradoxically better long-term survival than non-fulminant if patient survives initial period per McCarthy NEJM 2000)
    inputs: sbp, lactate, troponin
    advance: Risk stratified and recovery candidacy assessed
  8. 8TREATMENT
    Standard CS support (NE first-line per SOAP-II); inotropes CAUTIOUS in inflamed myocardium; MCS bridge (IABP / Impella / VA-ECMO) early; phenotype-specific: ACUTE COVID with cytokine storm → tocilizumab if IL-6 elevated per REMAP-CAP / RECOVERY; concurrent respiratory failure → dexamethasone (helps respiratory NOT myocardial — RECOVERY PMID 32678530); IVIG in fulminant per case series (uncontrolled); antiviral nirmatrelvir-ritonavir if within 5 d; AVOID NSAIDs in fulminant; VACCINE-ASSOCIATED usually mild → NSAID + colchicine + supportive (ACC 2022); fulminant vaccine — escalate as for any fulminant myocarditis
    inputs: sbp, lactate
    actions: cardiogenic_shock
    advance: Phenotype-appropriate therapy started + MCS plan documented
  9. 9DISPOSITION
    CICU at MCS-capable / transplant-capable center; advanced HF + transplant evaluation if refractory; arrhythmia management with EP; ID consult for COVID phenotype
    advance: Disposition assigned with MDT mobilised (cards, IC, advanced HF, transplant, EP, ID, oncology if MIS-A)
  10. 10MONITORING
    A-line, central line, lactate clearance, urine output; continuous telemetry; serial echo q24h for LV recovery trajectory; daily troponin and BNP; serial ECG for AV block; daily CRP / ferritin / IL-6 if cytokine storm therapy
    inputs: lactate, troponin
    actions: panel.cardiac, panel.renal
    advance: Monitoring cadence set + reassessment scheduled
  11. 11FOLLOWUP
    Repeat echo + CMR at 4-8 wks for recovery trajectory; cardiac rehab; GDMT 4-pillar if persistent HFrEF; EP follow-up for ICD eligibility; activity restriction × 3-6 mo per AHA 2015 / ESC 2020 sports cardiology + Drezner JACC 2022; vaccine continuation shared decision per CDC ACIP
    advance: Recovery echo, CMR, GDMT plan, ICD timeline, vaccine plan booked